adrenal gland disease: A disease involving the adrenal gland.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
174 |
4. Check minimum number of eventsNone |
174 |
5. Include endpointsNone |
174 |
6. Filter based on genotype QC (FinnGen only) |
174 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Disorders of adrenal gland, other and/or unspecified
based on the number of shared cases.
Similar with more cases:
- Other disorders of adrenal gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1308 | 813 | 486 |
| Only index persons | 1013 | 644 | 369 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.81 | 46.38 | 55.27 |
| Only index persons | 49.26 | 46.43 | 54.20 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 174 | 111 | 63 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | 49.75 | 44.18 | 59.55 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 163
- Matched controls
- 1629
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E27.9
ICD-10 Finland
Disorder of adrenal gland, unspecified
+∞
90.2
78
*
H02AB09
ATC
hydrocortisone; systemic
136.8
64.9
66
8
E27.8
ICD-10 Finland
Other specified disorders of adrenal gland
+∞
48.4
44
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
22.4
21
*
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
21.3
20
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
21.3
20
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
20.2
19
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
19.1
19.7
30
19
H02AA02
ATC
fludrocortisone; oral
106.9
18.0
19
*
25599
ICD-8 Finland
Diseases of adrenal glands, Other and unspecified
+∞
15.9
15
*
2559X
ICD-9 Finland
Disorders of adrenal glands, Unspecified disorder of adrenal glands
+∞
12.7
12
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
11.6
11
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
11.6
11
*
25598
ICD-8 Finland
Diseases of adrenal glands, Alii definiti
+∞
10.5
10
*
E23.03
ICD-10 Finland
Lack of ACTH
+∞
10.5
10
*
C03DA01
ATC
spironolactone; oral
5.5
10.0
30
64
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
9.8
38
107
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
19.0
9.6
14
8
R06.0
ICD-10 Finland
Dyspnoea
3.4
9.6
54
207
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
105.9
9.5
10
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
9.1
35
97
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
8.4
84
463
M05BA04
ATC
alendronic acid; oral
5.0
8.2
26
59
C03CA01
ATC
furosemide; systemic
2.9
8.2
59
265
R53
ICD-10 Finland
Malaise and fatigue
3.0
7.9
52
217
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
47.3
7.8
9
*
H02AB06
ATC
prednisolone; systemic
2.6
7.8
93
557
SPAT1301
SPAT
No procedures
2.7
7.6
66
329
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
7.3
7
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
16.7
7.3
11
7
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
5.0
7.3
23
52
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.7
7.1
60
293
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.5
7.0
73
398
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
4.8
6.9
22
51
A06AC01
ATC
ispaghula (psylla seeds); oral
2.8
6.9
52
237
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
6.8
66
346
N06AX21
ATC
duloxetine; oral
3.6
6.7
31
101
A10BA02
ATC
metformin; oral
2.7
6.7
51
232
M54.5
ICD-10 Finland
Low back pain
2.5
6.7
65
340
N03AX12
ATC
gabapentin; oral
3.1
6.6
37
139
M79.6
ICD-10 Finland
Pain in limb
2.4
6.6
71
391
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.0
6.6
41
166
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.2
6.5
36
133
R51.80
ICD-10 Finland
Headache
3.3
6.5
35
125
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.9
6.5
45
192
103
Kela drug reimbursment
Diabetes, insulin-treated
2.7
6.5
48
215
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.7
6.4
28
87
N92.1
ICD-10 Finland
Excessive and frequent menstruation with irregular cycle
5.5
6.4
18
36
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.9
6.4
40
163
AA1AD
NOMESCO Finland
CT of head and brain
2.7
6.2
47
213
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
7.2
6.2
14
21
R03AC12
ATC
salmeterol; inhalant
6.0
6.2
16
29
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
6.1
46
207
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
87
116
14.00
68.38
5.7
1.7
298.2
383.8
nmol/l
1.08
77
104
21
21
11.24
18.86
3.1
2.3
5.1
5.0
kpa
0.14
21
21
16
11
15.92
17.85
1.4
1.2
—
—
—
0
0
42
105
4.95
16.36
4.7
3.1
1.2
1.2
mmol/l
0.73
37
86
17
17
10.97
15.16
1.3
2.5
15.1
16.3
%
—
5
9
14
11
13.75
14.42
1.2
1.5
91.2
91.0
%
0.05
14
11
21
30
7.82
14.32
1.4
1.2
9.7
9.7
u/l
0.00
14
22
119
657
3.57
14.09
11.5
5.7
1.2
1.2
mmol/l
0.77
89
556
31
79
4.56
11.60
10.6
8.4
25.0
25.1
mmol/l
0.05
31
79
84
415
2.98
11.30
5.1
2.2
57.3
53.1
u/l
0.37
79
384
106
597
2.98
11.16
11.8
5.3
1.2
1.2
mmol/l
1.32
96
539
31
86
4.17
10.36
5.4
3.2
4.8
4.4
pmol/l
1.47
25
75
29
82
4.04
9.42
4.9
2.8
82.3
72.0
ng/l
0.21
24
76
37
127
3.43
9.07
4.2
2.9
—
—
—
0
0
122
792
2.81
9.01
9.0
4.5
7.0
6.5
mmol/l
1.40
117
735
73
372
2.66
8.79
3.6
3.3
838.8
1039.4
ng/l
0.30
64
315
14
23
6.53
8.32
2.4
2.3
2.0
2.3
%
0.07
14
15
10
11
9.58
8.16
2.4
1.5
5.9
3.4
nmol/l
—
10
11
95
566
2.49
8.06
4.1
2.2
77.3
75.4
nmol/l
0.30
88
499
62
303
2.63
8.00
2.0
1.8
0.7
0.9
mg/l
0.49
44
235
80
442
2.50
7.98
3.4
3.0
2.3
2.4
mmol/l
0.55
75
392
27
82
3.71
7.90
5.7
5.5
5.3
5.1
kpa
0.95
27
73
42
173
2.88
7.49
3.5
2.1
23.7
22.5
%
0.15
33
147
84
486
2.41
7.44
4.1
3.2
—
—
—
0
0
87
519
2.35
7.10
5.7
3.8
30.9
38.4
ng/l
0.28
71
346
110
730
2.38
6.96
9.7
5.5
11.0
11.8
umol/l
0.14
101
690
44
195
2.68
6.79
4.7
3.3
0.8
0.8
mmol/l
0.11
44
185
84
503
2.30
6.69
2.2
1.9
92.7
95.1
pmol/l
0.19
49
253
99
635
2.30
6.69
4.5
2.5
135.8
92.4
ug/l
1.09
92
584
31
116
3.03
6.51
4.7
4.6
2.7
2.2
mmol/l
0.43
23
89
13
26
5.32
6.33
4.2
3.2
62.0
59.4
%
0.25
13
26
37
157
2.72
6.17
25.6
24.0
1.1
1.3
inr
—
7
16
140
1066
2.60
6.06
13.1
6.8
77.5
76.4
u/l
0.15
129
990
70
402
2.24
6.03
2.6
2.1
141.8
136.7
u/l
0.06
64
382
53
272
2.36
5.93
2.4
1.6
452.6
21459677.0
pmol/l
0.50
45
233
43
201
2.51
5.90
2.4
1.9
—
—
—
0
0
27
101
2.98
5.65
1.1
1.2
91.8
110.3
iu/ml
—
6
40
46
228
2.38
5.53
2.4
1.6
1215.1
1194.9
nmol/l
0.05
37
171
66
384
2.16
5.40
4.1
3.0
0.3
0.4
e6/l
0.15
53
284
15
40
4.01
5.21
1.4
1.2
—
—
—
0
0
113
812
2.12
5.21
9.2
8.7
4.7
4.1
e9/l
1.67
107
704
21
71
3.23
5.19
1.7
1.3
24.4
26.8
iu/l
0.10
16
62
134
1046
2.22
4.75
7.0
3.9
10.6
10.7
mm/h
0.06
124
953
11
26
4.45
4.42
3.9
3.2
5.0
5.0
e9/l
0.01
11
26
43
227
2.19
4.39
4.8
3.2
57.4
61.1
ng/l
0.03
31
168
12
31
4.08
4.33
3.3
2.9
27.5
25.2
mmol/l
0.78
12
25
12
32
3.95
4.16
1.8
1.1
—
—
—
0
0
16
53
3.22
4.08
7.2
6.9
25.0
24.5
mmol/l
0.24
16
53
150
1258
2.39
3.97
7.7
5.1
41.5
39.1
mmol/mol
1.62
143
1181
7
8
9.05
3.81
2.0
2.1
—
—
—
0
0
21
85
2.67
3.80
2.8
1.4
—
—
—
0
0
6
5
12.36
3.79
1.0
1.0
—
—
—
0
0
60
376
1.91
3.78
6.0
4.0
0.0
0.0
estimate
0.00
32
120
11
30
3.85
3.70
1.2
1.7
—
—
—
0
0
38
205
2.09
3.63
2.9
2.8
4.1
3.0
e6/l
0.30
26
101
9
17
5.52
3.56
2.3
1.1
—
—
—
0
0
8
13
6.39
3.54
1.3
1.2
—
—
—
0
0
44
259
1.94
3.29
1.6
1.3
45.2
29.9
iu/ml
0.17
11
84
54
341
1.85
3.26
1.5
1.2
1.1
0.9
u/ml
0.14
16
88
11
33
3.49
3.25
3.3
2.5
—
—
—
0
0
160
1412
2.65
3.24
38.1
14.4
139.3
139.7
mmol/l
0.99
154
1364
152
1315
2.23
3.18
5.5
4.2
5.9
5.8
mmol/l
0.51
141
1219
77
544
1.75
3.18
6.5
3.6
—
—
—
0
0
160
1416
2.62
3.15
38.1
14.4
3.9
4.0
mmol/l
0.78
154
1369
29
149
2.14
3.13
14.1
5.8
1.8
1.3
mmol/l
0.39
24
115
19
82
2.48
3.04
2.1
1.3
—
—
—
0
0
5
5
10.24
2.99
1.2
1.2
66.8
73.4
u/l
—
5
5
159
1416
2.43
2.85
31.1
13.0
22.3
22.3
mg/l
0.01
140
1108
27
140
2.10
2.85
2.6
1.8
—
—
—
0
0
17
72
2.51
2.82
2.5
1.6
—
—
—
0
0
83
615
1.67
2.78
5.0
3.7
—
—
—
0
0
48
310
1.76
2.64
2.0
1.5
18.8
20.4
nmol/l
0.33
41
256
9
25
3.74
2.61
1.1
1.4
—
—
—
0
0
26
139
2.02
2.53
2.7
1.7
—
—
—
0
0
90
697
1.60
2.43
6.2
3.5
0.0
0.0
estimate
0.00
32
126
8
22
3.76
2.39
1.3
1.7
—
—
—
0
0
90
702
1.58
2.33
8.0
4.7
0.0
0.0
estimate
0.00
31
123
91
714
1.58
2.28
6.2
3.5
0.0
0.0
estimate
0.00
28
122
7
18
4.01
2.27
1.0
1.1
—
—
—
0
0
5
9
5.68
2.23
1.4
1.1
—
—
—
0
0
5
9
5.68
2.23
1.2
1.7
—
—
—
0
0
5
9
5.68
2.23
1.2
1.7
—
—
—
0
0
147
1303
1.83
2.19
29.0
11.7
81.3
82.7
ml/min/173m2
0.28
133
1064
12
49
2.56
2.15
2.0
1.7
0.9
6.3
ug/l
0.48
12
44
9
31
3.00
2.10
1.2
1.7
—
—
—
0
0
7
20
3.60
2.08
1.1
1.4
—
—
—
0
0
14
63
2.33
2.07
2.6
5.3
0.8
1.4
%
1.55
14
63
11
46
2.49
1.89
2.2
2.1
—
—
—
0
0
5
12
4.26
1.83
1.6
1.2
—
—
—
0
0
144
1290
1.67
1.80
8.7
4.7
1.7
1.9
mu/l
1.09
136
1191
12
54
2.31
1.78
2.2
2.1
—
—
—
0
0
6
18
3.41
1.76
1.2
1.7
—
—
—
0
0
34
223
1.65
1.74
3.0
2.7
0.8
1.0
e6/l
0.27
23
118
5
14
3.64
1.62
1.0
1.0
—
—
—
0
0
38
262
1.58
1.60
1.6
1.3
1.0
8.4
u/ml
—
9
103
7
27
2.66
1.53
6.0
1.3
—
—
—
0
0
51
379
1.49
1.53
1.5
1.6
1.5
1.3
mmol/l
0.60
40
315
0
45
0.00
1.52
0.0
1.6
—
—
—
0
0
9
39
2.38
1.45
1.3
1.5
—
—
—
0
0
5
16
3.18
1.45
1.4
1.3
—
—
—
0
0
6
22
2.79
1.44
1.7
1.4
—
—
—
0
0
6
23
2.66
1.38
1.2
1.7
—
—
—
0
0
14
78
1.86
1.25
17.6
7.4
0.5
0.7
%
2.17
14
78
22
142
1.63
1.21
4.7
2.2
29.3
29.2
u/l
0.00
17
120
14
79
1.84
1.21
17.6
7.3
1.7
1.6
%
0.06
14
79
10
51
2.02
1.13
2.1
1.8
—
—
—
0
0
7
31
2.31
1.11
1.0
1.1
—
—
—
0
0
26
179
1.53
1.11
2.0
2.1
—
—
—
0
0
141
1300
1.45
1.10
4.5
3.8
1.5
1.2
mmol/l
2.44
124
1206
34
251
1.44
1.05
2.6
2.9
2.5
2.4
mmol/l
1.02
28
223
9
47
1.96
1.04
1.1
2.4
—
—
—
0
0
109
969
1.33
1.03
6.1
2.7
50.6
41.9
u/l
0.86
99
914
146
1361
1.45
1.01
4.9
4.2
4.7
4.7
mmol/l
0.26
134
1272
5
23
2.21
0.98
1.4
1.6
—
—
—
0
0
156
1479
1.53
0.91
35.6
14.6
78.3
74.6
umol/l
0.51
156
1479
144
1348
1.40
0.88
4.9
4.2
1.5
1.5
mmol/l
0.90
129
1251
147
1381
1.42
0.88
5.3
4.7
2.7
2.8
mmol/l
0.49
133
1278
6
30
2.03
0.88
2.5
1.4
—
—
—
0
0
6
30
2.03
0.88
2.5
1.4
—
—
—
0
0
8
47
1.74
0.82
1.3
1.2
—
—
—
0
0
8
47
1.74
0.82
1.3
1.2
—
—
—
0
0
5
24
2.11
0.75
1.4
1.5
—
—
—
0
0
5
24
2.11
0.75
1.4
1.5
—
—
—
0
0
38
304
1.32
0.74
3.5
2.1
—
—
—
0
0
9
56
1.64
0.73
1.8
1.4
—
—
—
0
0
26
197
1.38
0.71
2.2
2.2
—
—
—
0
0
15
107
1.44
0.57
2.0
2.4
11.0
4.5
ug/l
0.56
15
94
155
1493
1.35
0.55
17.8
9.4
25.4
25.1
u/l
0.09
150
1439
23
285
0.78
0.48
3.4
4.3
24.9
20.7
%
0.69
14
134
7
47
1.51
0.48
1.7
2.1
—
—
—
0
0
20
157
1.31
0.46
3.8
4.3
33.5
31.1
%
0.43
14
98
34
289
1.22
0.42
2.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.2
1.2
—
—
—
0
0
5
34
1.48
0.40
1.6
1.6
—
—
—
0
0
134
1284
1.19
0.39
32.0
13.4
36.5
40.2
%
2.03
84
986
99
928
1.16
0.38
3.9
3.2
—
—
—
0
0
5
36
1.40
0.38
1.0
1.3
—
—
—
0
0
5
79
0.62
0.36
1.8
1.5
—
—
—
0
0
6
43
1.41
0.35
1.2
2.5
0.0
1.3
g/l
—
6
38
6
44
1.38
0.35
1.7
1.3
—
—
—
0
0
6
47
1.29
0.32
1.2
1.1
—
—
—
0
0
5
40
1.26
0.22
1.0
2.5
34.1
38.1
g/l
—
5
34
0
11
0.00
0.21
0.0
2.5
—
17.3
—
0
11
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
9
80
1.13
0.15
1.1
1.0
—
—
—
0
0
29
271
1.08
0.10
1.4
1.4
—
—
—
0
0
37
350
1.07
0.10
5.7
4.7
3.8
2.0
ug/l
0.52
31
313
19
205
0.92
0.08
2.7
2.8
2.5
0.7
ug/l
0.55
14
128
9
104
0.86
0.06
1.9
2.0
—
—
—
0
0
15
156
0.96
0.00
9.3
7.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
270.6
—
0
9
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
8
83
0.96
0.00
1.5
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
2.6
—
237.8
—
0
5
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
8
87
0.92
0.00
1.3
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
9.0
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint E4_ADRENAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADRENAS | 2.633 [1.78, 3.89] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.58 |
During the follow-up period (1.1.1998 — 31.12.2019), 81 out of 411 females with E4_ADRENAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADRENAS | 2.646 [1.65, 4.25] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.007 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 264 males with E4_ADRENAS died.
Mortality risk
Mortality risk for people of age
years, who have E4_ADRENAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.191% | 0.525% |
| 5 | 1.462% | 3.045% |
| 10 | 3.893% | 7.638% |
| 15 | 7.674% | 14.4% |
| 20 | 13.363% | 23.783% |
Relationships between endpoints
↥Index endpoint: E4_ADRENAS – Disorders of adrenal gland, other and/or unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data